Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Dual-Trained Rheumatologists Take Multidisciplinary Approach to Their Patients

Gretchen Henkel  |  Issue: October 2015  |  October 14, 2015

As a result, Dr. Despotovic chose a fellowship in rheumatology but also retained and continued to nurture his interest in critical care. Shortly after completing his two-year rheumatology fellowship in 1999 at Washington University, he decided to do a critical care fellowship. Combining the two was, at the time, an unusual step. “To most people, this [choice] did not look like straightforward career decision making,” he says. After completing his second fellowship, he realized that he wanted to combine both skillsets in his clinical practice. “The pace of work in the inpatient hospital environment fits me better than the outpatient environment,” he states.

Dr. Despotovic maintains that his biggest challenge was establishing his legitimacy in both fields. His immediate mentors, among them John Atkinson, MD, head of the rheumatology division, and Richard D. Brasington, MD, professor of medicine in the division of rheumatology, were “exceptional role models,” he says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the beginning, he perceived “an extra layer of questioning” from colleagues because the rheumatology/critical care specialist was not a defined niche. “Once people realize you can do both things with the same amount of passion, that doubt goes away.”

His current interests in the ICU environ­ment encompass vasculitis and connective tissue disease-associated interstitial lung disease (CTD-ILD). He often interacts with his pulmonary colleagues at his institution’s ILD clinic. He finds these collaborations “a productive relationship. I think the collaboration makes us all better doctors,” he says. He also attends at his institution’s medical critical care unit in Barnes-Jewish Hospital for two-week-long blocks. If there were enough patients to warrant the volume, Dr. Despotovic quips, “the perfect position for me would be as a rheumatology intensivist.” (Indeed, in practice both he and Dr. Dellaripa do function in that role, he notes.)

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Synergy of 2 Fields

Will obtaining credentials as rheumatologists/critical care specialists become a trend? Both Drs. Despotovic and Dellaripa say it’s too early to tell. Dr. Despotovic reports that some of his trainees have inquired about following his path. “I try not to talk them into it just because I have done this,” he says. “I mention the challenges I have encountered and advise that they must have persistence. I want to make sure they are choosing the right career path for themselves.”

Dr. Dellaripa is enthusiastic about the additional synergy that has been created through the collaborations in the ILD clinic. He has also collaborated with pulmonary colleagues Aryeh Fischer, MD, and Kevin R. Flaherty, MD, to edit a new text: Pulmonary Manifestations of Rheumatic Disease, A Comprehensive Guide.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Career DevelopmentConditionsProfessional TopicsRheumatoid Arthritis Tagged with:ClinicalDiagnosislung disorderpatient careRARheumatoid arthritisrheumatologistrhuematologyTreatment

Related Articles

    What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

    December 1, 2012

    Patients with systemic sclerosis (SSc), poly-/dermatomyositis (PM/DM), or rheumatoid arthritis (RA) appear to carry the greatest risk for developing connective tissue disease-associated interstitial lung disease (CTD-ILD)
     

    Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

    June 15, 2022

    No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

    New Africa / shutterstock.com

    A Rheumatologist & Pulmonologist Discuss RA-ILD

    November 14, 2021

    Introduction The understanding and treatment of rheuma­toid arthritis (RA) has evolved dramatically in the past 20 years. As gains have been made in treating joint disease in RA, our understanding of the impact of extra-articular manifestations of RA, such as cardiac and lung disease—specifically interstitial lung disease (ILD)—has gradually increased. While rheumatologists increasingly appreciate the…

    Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease

    September 22, 2021

    Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences